尼波卡利马布是一种免疫选择性FcRn阻断剂,降低IgG,具有独特的分子特性
Nilufer P Seth1, Rui Xu1, Matthew DuPrie1
1Johnson & Johnson, USA.
mAbs
|February 12, 2025
概括
尼波卡利马布是一种针对新生儿Fc受体 (FcRn) 的抗体,有效降低了致病性免疫球蛋白G (IgG) 水平. 非临床研究证实了其在治疗IgG介导的自身免疫和所有抗体疾病方面的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 结构生物学 结构生物学
背景情况:
- 尼波卡利马布是一种人类IgG1单克隆抗体,旨在向新生儿Fc受体 (FcRn).
- 在IgG的恒温和循环中,FcRn起着至关重要的作用.
- 对IgG水平的调节失调与各种自身免疫和所有抗体介导疾病有关.
研究的目的:
- 描述尼波卡利马布的分子,细胞和非临床性质.
- 支持尼波卡利马布的临床药理学和潜在的治疗应用.
- 为了阐明尼波卡利马布与FcRn.的结合机制.
主要方法:
- 进行X射线晶体学以确定尼波卡利马布Fab/FcRn复合物的结构.
- 基于细胞的测试以评估FcRn占用率和IgG减少.
- 在小鼠和Cynomolgus子体内研究,以评估药理动力学和药理动力学效应.
主要成果:
- 晶体结构显示nipocalimab与一个独特的FcRn表位结合,这解释了其高的pH独立亲和力.
- 证明了剂量和时间依赖的FcRn占用率和循环IgG水平的降低.
- 证实了选择性IgG降低,而不会影响其他免疫功能.
结论:
- 尼波卡利马布表现出高亲和度,pH值独立的结合FcRn.
- 非临床数据支持尼波卡利马布在减少致病性IgG的有效性.
- 尼波卡利马布显示出作为IgG驱动疾病的治疗剂的潜力.
更多相关视频
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141